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Edited by Barry HalliwellAbstract Memantine, an N-methyl-D-aspartate (NMDA) re-
ceptor antagonist, reduces the clinical deterioration in moderate-
to-severe Alzheimer disease (AD) for which other treatments are
not available. The activity of protein phosphatase (PP)-2A is
compromised in AD brain and is believed to be a cause of the
abnormal hyperphosphorylation of tau and the consequent
neuroﬁbrillary degeneration. Here we show that memantine
inhibits and reverses the PP-2A inhibition-induced abnormal
hyperphosphorylation and accumulation of tau in organotypic
culture of rat hippocampal slices. Such restorative eﬀects of
memantine were not detected either with 5,7-dichlorokynurenic
acid or with D())-2-amino-5-phosphopentanoic acid, NMDA
receptor antagonists active at the glycine binding site and at the
glutamate binding site, respectively. These ﬁndings show (1) that
memantine inhibits and reverses the PP-2A inhibition-induced
abnormal hyperphosphorylation of tau/neuroﬁbrillary degenera-
tion and (2) that this drug might be useful for the treatment of
AD and related tauopathies.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Alzheimer disease; Protein phosphatase-2A;
NMDA receptor; Tau hyperphosphorylation; Memantine;
Neuroﬁbrillary degeneration1. Introduction
Neuroﬁbrillary degeneration, which is a hallmark of Alz-
heimer disease (AD) and related tauopathies such as fronto-
temporal dementia, correlates directly with dementia [1,2].
Microtubule associated protein tau is abnormally hyper-* Corresponding author. Fax: +1-718-494-1080.
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nopentanoic acid; cdk5, cyclin dependent protein kinase 5; CaMKII,
calcium, calmodulin-dependent protein kinase II; DK, 5,7-dichloroky-
nurenic acid; LDH, lactate dehydrogenase; MAP, microtubule asso-
ciated protein; MAPK, mitogen-activated protein kinase; NF-H/M,
neuroﬁlament-heavy/medium; NMDA, N-methyl-D-aspartate; OA,
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sulfonyl ﬂuoride; PP, protein phosphatase
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form is the major protein subunit of the neuroﬁbrillary chan-
ges [3]. The biological activity of tau is regulated by its degree
of phosphorylation [4]. While normal tau promotes the as-
sembly and maintains the structure of microtubules, the ab-
normally hyperphosphorylated form of this protein in AD
cytosolic abnormally hyperphosphorylated tau (AD P-tau)
instead sequesters normal tau, microtubule-associated protein
1 (MAP1) and MAP2 and causes disassembly of microtubules
[5,6]. This toxic property of the AD P-tau, which through the
breakdown of the microtubule network can compromise ax-
onal transport and lead to neurodegeneration, appears to be
solely due to its abnormal hyperphosphorylation because
dephosphorylation by a phosphatase restores it into a normal-
like protein in vitro [6,7]. The activity of phosphoseryl/phos-
phothreonyl protein phosphatase (PP)-2A, which regulates the
phosphorylation of tau [8,9] is compromised in AD brain
[10,11] and is believed to be a cause of the abnormal hyper-
phosphorylation of tau. A recent study has shown that the
N-methyl-D-aspartate (NMDA) receptor is in a complex with
PP-2A and that stimulation of this receptor can lead to the
dissociation of PP-2A from the complex and the reduction of
PP-2A activity in cultured cells [12]. Memantine is a low to
moderate aﬃnity uncompetitive NMDA receptor antagonist
which leads to functional improvement and reduces care de-
pendence in moderate to severe AD patients [13,14].
We show the eﬀect of memantine on the abnormal hyper-
phosphorylation of tau and the protein kinases (PKAs) and
PPs involved in organotypic culture of rat hippocampal slices
in which PP-2A activity was inhibited by okadaic acid (OA).
Memantine reversed the OA-induced decrease in PP-2A ac-
tivity, increase in calcium, calmodulin-dependent protein ki-
nase II (CaMKII) and cyclin AMP-dependent PKA activities
and abnormal hyperphosphorylation of tau to the control le-
vel, and inhibited the neurodegeneration associated with these
changes. It reversed the decrease and aggregation of MAP2
and the phosphorylation and aggregation of neuroﬁlament-
heavy/medium (NF-H/M) subunits. Such eﬀects of memantine
were not detected either with 5,7-dichlorokynurenic acid (DK)
or with D())-2-amino-5-phosphonopentanoic acid (AP),
NMDA receptor antagonists active at the glycine binding and
the glutamate binding sites. These ﬁndings suggest (1) that
memantine can inhibit and reverse the Alzheimer type abnor-
mal hyperphosphorylation of tau and neuroﬁbrillary degen-
eration and (2) that this eﬀect of memantine might involve
modulation of PP-2A signaling in addition to its activity as an
NMDA antagonist.ation of European Biochemical Societies.
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2.1. Hippocampal organotypic cultures
Organotypic cultures of rat hippocampal slices were prepared from
20–30 day old Wistar rats and cultured with the interface method as
described previously [15]. Slices were treated with OA (Ammonium salt
from CalBiochem, La Jolla, CA) to inhibit PP-2A activity, glutamate
(Sigma–Aldrich, St. Louis, MO) as an NMDA receptor agonist and
memantine (a gift from Merz Pharmaceuticals, Frankfurt, Germany),
DK (Sigma–Aldrich) and AP (Sigma–Aldrich) as NMDA receptor
antagonists. When the slices were treated, the reagents were applied
into the culture medium. At diﬀerent time points, the slices collected
with a brush were washed twice and then homogenized at 4 C using a
Teﬂon-glass homogenizer in 50 mM HEPES, pH 7.0, 10 mM b-
merceptoethanol (BME), 1 mM EDTA, 1 mM EGTA, 0.1 mM phe-
nylmethyl sulfonyl ﬂuoride (PMSF), 2.0 mM benzamidine and 2.0 lg/
ml each of aprotinin, leupeptin and pepstatin. The homogenate was
then divided into two parts, one was centrifuged at 16 000 g for 15
min and the supernatant was used to assay activities of PP-2A and
PP-1. The rest of the homogenate was diluted 1:1 with a phosphatase
inhibitor cocktail (20 mM b-glycerophosphate, 2 mMNa3VO4 and 100
mM NaF, pH 7.0) and either used for Western blots or centrifuged at
16 000 g for 15 min and the resulting supernatant used to determine
the kinase activities.
2.2. Protein phosphatase assays
Activities of PP-2A and PP-1 were assayed towards [32P] phos-
phorylase-a as a substrate as described previously [16]. A PP-1 speciﬁc
inhibitor, inhibitor-1 was included in the assays for PP-2A activity. PP-
1 activity was calculated by subtracting the PP-2A activity from the
total phosphorylase-a phosphatase activity (PP-1/PP-2A) assayed in
the absence of inhibitor-1.2.3. PKA assays
CaMKII activity was assayed as described [17] using a reaction
mixture containing 50 mM HEPES, pH 7.5, 10 mM MgCl2, 2.0 mM
CaCl2, 10 mM BME, 10 lg/ml calmodulin (CaM), 20 lM syntide
(Sigma, St. Louis MO, USA), 0.06 mg/ml slice extract and 200 lM
[c32P] ATP. The activity of cyclic AMP-dependent PKA was deter-
mined as above except the reaction mixture contained 70 mM
NaHPO4, pH 6.8, 14 mM MgCl2, 1.4 mM EDTA, 30 lM malantide
(Sigma, St. Louis, MO, USA), 200 lM [c32P] ATP and 0.06 mg/ml slice
extract. Mitogen-activated protein kinase (MAPK) activity was de-
termined as described previously [18].
2.4. Radioimmuno-dot-blots and Western blots
Levels of phosphorylation of tau at diﬀerent sites were assayed by
the radioimmuno-dot-blots of the slice homogenates (4 lg protein/dot)
as described previously [19]. The primary tau antibodies used were as
follows: polyclonal antibodies (pAbs) pS-262 (1:1000) to P-Ser-262
(Bio-source), pS-212 (1:1000) to P-Ser 212 (Bio-source), pS-214
(1:1000) to P-Ser 214 (Bio-source), R145d (1:3000) to P-Ser 422 [18],
R134d (1:5000) to total tau [20] or monoclonal antibodies (mAbs)
PHF-1 (1:200) to P-Ser 396/404 [21,22] and 12E8 (1:500) to P-Ser-262/
356 [23]. The phosphorylation of tau at Ser-262 and the levels of
MAP2 and phosphorylated NF-H/M were assayed by [125I] Western
blots (30 lg homogenate/lane), using pAb pS-262 (1:1000, Biosource)
or mAb SMI 31 to phosphoneuroﬁlaments-H/M subunits (pNF-H/M),
or mAb SMI 52 to MAP2 (both from Sternberger Monoclonals, Inc.)
as primary antibodies and [125I] radiolabeled secondary antibodies
(Amersham).
2.5. Immunohistochemistry
After diﬀerent treatments some of the hippocampal slices were ﬁxed
in periodate/lysine/paraformaldehyde solution [24] at 33 C for 5 h and
then kept in 1% Triton X-100 in PBS (pH 7.4) and 0.1% NaN3 for 72 h
at room temperature. The slices were then incubated in blocking so-
lution containing PBS, 0.1% Triton X-100 and 10% normal horse se-
rum for 3 h at room temperature. Thereafter, the slices were rinsed in
PBS and incubated for 2 days in primary antibody at 4 C. The pri-
mary antibodies used were as follows: mAb SMI 31 to pNF-H/M
(1:10 000), mAb SMI 52 to MAP2 (1:20 000) and pAb pS-262 (1:1000)
to tau phosphorylated at Ser-262. The immunoreactivity was visual-
ized by incubation with peroxidase-conjugated goat antimouse/rabbitIgG (1:1000, Jackson) for 3 h at 37 C, followed by 0.05% diam-
inobenzidine (DAB) and H2O2 (0.01%) for 10 min.
2.6. Lactate dehydrogenase (LDH) activity and protein
The LDH released into the culture medium from the slices was de-
termined colorimetrically using Cytotox 96R Non-Radioactive Cyto-
toxicity Assay Kit (Promega, Madison, WI) according to the
manufacturer’s protocol. Protein concentrations were assayed by the
modiﬁed Lowry method [25].3. Results
3.1. Okadaic acid (OA) inhibits PP-2A and stimulates
CaMKII activity
OA is an extensively studied experimental irreversible non-
competitive inhibitor of PP-2A and PP-1 [26]. We elected to
employ for the present study as a model the organotypic cul-
ture of rat hippocampal slices in which the PP-2A activity was
inhibited by OA. This ex vivo system provides a direct and
practical access to mammalian brain for studying the eﬀect of
pharmacological compounds on the biology of speciﬁc pro-
teins and the cascades involved.
OA inhibited PP-2A activity in the hippocampal slice cul-
tures in a time- (3–48 h) and concentration- (10–1000 nM)
dependent manner (Fig. 1(a)). We found that 10 nM OA in-
hibited 20% of PP-2A activity during 24 h treatment. OA
concentrations of 100 nM and 1 lM resulted in 40% and
65% inhibition of PP-2A activity, respectively, during 24 h
treatment. Treatment up to 48 h at either concentration of OA
produced an additional 20–30% inhibition of PP-2A activity.
In agreement with previous studies in which metabolically
active rat brain slices were treated with 0.1–5 lMOA up to 3 h
[8,9,27] no inhibition of PP-1 activity was detected (Fig. not
shown).
Several PKA activities are known to be regulated by re-
versible phosphorylation and some of these kinases are sub-
strates for PP-2A. We found that the CaMKII activity
increased with increase in the inhibition of PP-2A activity by
OA treatment (Fig. 1(b)). An increase of 20%, 70% and
140%, respectively, was observed in cultures treated with 10,
100 and 1000 nM OA for 3–48 h. An increase of 20% was
observed in PKA activity in the slice cultures treated with 100
nM OA for 24 h or 48 h but not for 3 h (Fig. 2(c)). However,
no signiﬁcant change in the activities of GSK-3 or cyclin de-
pendent protein kinase 5 (cdk5) in the OA-treated cultures was
detected (Fig. not shown). The cell death in the cultures as
determined by assaying LDH activity released in the culture
medium was markedly increased both with increase in the OA
concentration up to 1 lM and duration of the treatment up to
48 hours studied (Fig. 1(c)). To keep cytotoxic eﬀects of OA
low and to have a model of a signiﬁcant inhibition of PP-2A
activity, we chose the treatment of the slice cultures with 100
nM of the drug for all subsequent studies.3.2. Memantine restores the OA-altered PP-2A, CaMKII and
PKA activities to the normal level
The activity of CaMKII is stimulated by Ca2þ/CaM through
its autophosphorylation at Thr-286/287 and is regulated by
PP-2A which dephosphorylates this site [9]. Thus, stimulation
of CaMKII activity by inhibition of PP-2A provided a very
useful non-NMDA pathway model of a protein phosphory-
lation/dephosphorylation imbalance. Employing this model we
Fig. 2. Restoration of activities of PP-2A and CaMKII to normal level
and inhibition of LDH release by memantine in OA-treated hippocampal
slices. (a)–(c) The slices in culture were treated without control or with 100
nMOA for 3, 24 or 48 h, followed by wash to remove OA and treatment
with 0, 1, 10 or 30 lM memantine for 24 h. The phosphatase and
the kinase activities were expressed as the percentage of the corresponding
activities of slices treated with medium alone (control) in culture. Bars
represent means S.D. obtained from at least three independent assays.
(a) Memantine restored the PP-2A (P < 0:02) and (b) CaMKII activities
(P < 0:02) to normal level and had no signiﬁcant eﬀect on activities
in control hippocampal slices. (c) As low as 1 lM memantine restored
the OA-induced increase in PKA activity to normal level (P < 0:05)
and (d) completely inhibited the OA-induced cell death (P < 0:001).
Fig. 1. Inhibition of PP-2A and stimulation of CaMKII activities, and
release of LDH by OA in hippocampal slices in culture. Hippocampal
slices were treated with either medium alone (control) or with OA. The
phosphatase and CaMKII activities were expressed as means S.D.
obtained from at least three independent assays. (a) PP-2A activity as
% of control-treated slices. A decrease of 42% (P < 0:05) and 78%
(P < 0:01) in PP-2A activity was observed in slices treated with 100 nM
OA for 24 h and with 1000 nM OA for 48 h, respectively. (b) CaMKII
activity increased to 180% (P < 0:01) and 240% (P < 0:01) in hippo-
campal slices treated for 24 h with 100 and 1000 nM OA, respectively.
(c) The cell death as assayed by LDH activity released in the medium
(ratio of LDH activity before/after OA treatment) increased with in-
crease in OA concentration and treatment period (P < 0:001).
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tau and the PKA and PP activities involved. We found that 10
lM memantine during 24 h restored the OA-induced changes
in the activities of PP-2A, CaMKII and PKA to normal levels
(Fig. 2(a)–(c)). Memantine had no signiﬁcant eﬀect on the
activities of cdk5 or GSK-3 in the OA-treated cultures
(Fig. not shown), or the activities of PP-2A, CaMKII or PKAin the control/untreated cultures (Fig. 2(a)–(c)). The eﬀect of
memantine on the restoration of PP-2A and CaMKII activities
could be observed at 1 lM concentration but the full eﬀect was
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memantine from 10 to 30 lM nor duration of the treatment
from 24 to 48 h resulted in any signiﬁcant additional eﬀect on
the restoration of either PP-2A or CaMKII activity. The OA-
induced cell death in the cultures was completely inhibited by 1
lM memantine during 24 h and by 10 lM of the drug by 3 h
(Fig. 2(d)). In the control cultures memantine had no eﬀect on
the LDH activity in the medium using 1–30 lM concentrations
of the drug investigated.3.3. Memantine restores tau phosphorylation to normal level
PP-2A downregulates the activity of CaMKII, a major tau
Ser-262 kinase in the mammalian brain [9,28]. Since we found
in the OA-treated hippocampal cultures a marked increase in
CaMKII activity and its restoration to normal level by me-
mantine, we studied in these cultures the eﬀect of these treat-
ments on the phosphorylation of tau at Ser-262 and as a
control at Ser-212, Ser-214, Ser-396/404 and Ser-422. Tau Ser-
212 is known to be phosphorylated by cdk5 and MAPK, Ser-
214 by PKA, Ser-396/404 by GSK-3b and cdk5 and Ser-422 by
stress activated PKAs [see 29]. We found a marked increase in
the phosphorylation of tau at Ser-262 and Ser-422 and a
modest increase at Ser-214, without any signiﬁcant change in
the level of total tau, in the OA-treated cultures (Fig. 3(a)).
Further treatment with 10 lMmemantine for 24 h restored the
tau phosphorylation at Ser-262 and Ser-214 to normal levels
(Fig. 3(a) and (b)). However, memantine had no eﬀect on the
OA-induced phosphorylation of tau at Ser-422 (Fig. 3(a)). We
found that 2 lMmemantine inhibited the tau phosphorylation
at Ser-262 and that this eﬀect was maximal at 5 lM concen-
tration of the drug (Fig. 3(c)).
Immunocytochemical staining of the untreated and treated
cultures with phosphodependent rabbit antibody to phospho
tau Ser-262 revealed a marked increase in the p-Ser-262
staining in cells in the area corresponding to stratum oriens
and alvus in the OA-treated cultures (Fig. 3(d)). Long pro-
cesses, presumably axons with irregular contour and short rod-
shaped fragments reminiscent of neuropil threads/degenerating
neurites were often seen along the outer regions of stratum
radiale (Fig. 3(d, ii)). In the cultures treated with 10 lM me-
mantine for 24 h following the OA treatment, the p-Ser-262
immunostaining of the neurons markedly decreased (Fig. 3(d,
iii)).Fig. 3. Restoration of OA-induced tau phosphorylation at Ser-262 to
normal level by memantine. The hippocampal slices in culture were
treated with or without (control) 100 nM OA for 24 h, washed and
then treated with (unless otherwise indicated) or without (control) 10
lM memantine for 24 h. (a) The immunoreactivities at diﬀerent sites
obtained with diﬀerent antibodies quantitated by a phosphorimager
and normalized against the level of total tau detected with pAb R134d.
(b) [125I] Western blots of the cultured hippocampal slices developed
with pAb pS-262: 1, control; 2, OA 24 h, then medium 24 h; 3, OA
24 h, then memantine 24 h. (c) Eﬀect of diﬀerent concentrations of
memantine on the restoration of the OA-induced phosphorylation of
tau at Ser-262 as determined by radioimmunodot-blots as in (a). The
data are the averages of two independent assays. (d) Immunocyto-
chemical staining showing tau phosphorylation at Ser-262 in cultured
hippocampal slices. i, Control, with medium only; ii, treated with 100
nM OA 24 h, then medium 24 h; iii, 100 nM OA 24 h, then memantine
24 h. The insets (ii) show at high magniﬁcation Ser-262 hyper-
phosphorylation and accumulation of tau in the somatodendritic
compartments of a neuron and in axons.3.4. Memantine inhibits aggregation of MAP2 and NFs
A protein phosphorylation/dephosphorylation imbalance in
the neuron might not only aﬀect the phosphorylation of tau
but like in AD, might also aﬀect other cytoskeletal proteins.
We found that following the OA treatment, the MAP2 im-
munostaining increased markedly in the somatodendritic
compartments of neurons, possibly interneurons, with a cor-
responding decrease in the neuropil in an area roughly corre-
sponding to stratum oriens (Fig. 4(a, i, ii)). Dystrophic
dendrites/neuropil threads with the characteristic of beaded
uneven contour, alternating swollen and shrunken segments
were seen, suggesting a degeneration of neurons. In the me-
mantine treated cultures a decrease in the degeneration and
restoration of the staining of the neuropil were observed
(Fig. 4(a, iii)). Western blots revealed a decrease in MAP2 in
the OA-treated cultures and a reversal to normal levels by
treatment with memantine (Fig. 4(b)).
Fig. 4. Restoration of OA-induced changes in MAP2 and NFs by memantine. (a) (i–vi) Immunocytochemical staining of MAP2 (i–iii) and NFs (iv–
vi) in cultured hippocampal slices. (i, iv) Control-treated; (ii, v) treated with 100 nM OA for 24 h, followed by medium for 24 h; (iii, vi) 100 nM OA 24
h, followed by 10 lM memantine, 24 h. (b) and (c) [125I] Western blots of slice homogenates showing changes in MAP2 (b) and NFs (c). Lane 1,
control; lane 2, treated with OA as in (a); lane 3, treated with OA and then with memantine as in (a).
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with antibodies to pNF-H/M revealed an increase in phos-
phorylation and accumulation of NF-H/M in the neuronal cell
bodies and their neurites in the areas corresponding to stratum
oriens and alveus. Thick tortuous, thread-like and beaded
fragmented neurites similar to neuropil threads were abun-
dantly seen in the OA treated cultures (Fig. 4(a, v)). Meman-
tine, 10 lM, during 24 h treatment partially reversed these
pathological changes (Fig. 4(a, vi)). Western blots of the OA-
and OA plus memantine-treated cultures conﬁrmed the re-
versal of phosphorylation of NF-H/M subunits by memantine
(Fig. 4(c)).
3.5. The restorative eﬀect of memantine on the activities of PP-
2A and CaMKII is through PP-2A signalling and not by its
interaction with OA
Since memantine only restored the OA-induced decrease in
PP-2A and increase in CaMKII but had no eﬀect on these
activities in the control-treated cultures, we investigated whe-
ther the memantine eﬀect was due to any direct interaction
with OA. We found that the removal of OA after 24 h treat-
ment restored the PP-2A and CaMKII activities slightly,
whereas the treatment of the cultures with both OA and me-
mantine for 24 h or with OA for 24 h, wash and then with
memantine for 24 h almost completely restored the two en-
zyme activities (Fig. 5(a) and (b)). These ﬁndings suggested
that the eﬀect of memantine on PP-2A and CaMKII activities
was unlikely to be through any direct interaction with OA and
that memantine could both inhibit and reverse these changes.
Furthermore, the addition of OA (100 nM) to a 16 000 g
extract of homogenate of untreated cultures inhibited 90% of
PP-2A activity and the addition of diﬀerent concentrations ofmemantine, 1–60 lM had no signiﬁcant eﬀect on the phos-
phatase activity (Fig. 5(c)). Similarly the addition of meman-
tine, 1–10 lM to the 16 000 g extract of the OA-treated
cultures failed to restore the PP-2A activity (Fig. 5(d)). All
these data taken together unequivocally demonstrated that
memantine restored PP-2A activity and probably as a conse-
quence the CaMKII activity through PP-2A signaling and not
by any direct interaction with OA.
3.6. Eﬀect of memantine on PP-2A and phosphorylation of tau
is primarily through modulation of PP-2A signalling
CaMKII can be activated either by autophosphorylation
resulting from inhibition of PP-2A or activation of NMDA
receptor. PP-2A is tethered to NR3A subunit of the NMDA
receptor. Stimulation of this receptor leads to dissociation and
decrease in the activity of PP-2A [12]. The NR3A subunit is,
however, greatly down-regulated in the adult and thus, stim-
ulation of the receptor in adult brain might not have any sig-
niﬁcant eﬀect on the PP-2A activity. We found that the
treatment of the hippocampal slice cultures with 0.3 mM
glutamate for 1 h (Fig. 6) but not 24 h (data not shown)
produced a marked increase in the phosphorylation of tau at
Ser-262. However, this change, which was transient, was as-
sociated only with an increase in CaMKII activity but not
accompanied by any detectable changes in the activities of PP-
2A or MAPK the activity of which is regulated by PP-2A
(Fig. 6). These studies suggested that in brain the activation of
the NMDA receptor by its natural agonist glutamate activated
CaMKII without aﬀecting the PP-2A activity, and that the
restoration of the OA-induced inhibition of the phosphatase
activity by memantine might therefore have been independent
of its activity as an NMDA receptor antagonist. To further
Fig. 5. Restoration of the activities of PP-2A and CaMKII of OA-treated hippocampal slices by memantine both when employed along with OA or
followed by OA treatment. The phosphatase and kinase activities of OA or memantine-treated samples were expressed as meansS.D. obtained
from at least three independent assays. (a) Restoration of PP-2A activity by memantine (P < 0:05). (b) Restoration of CaMKII activity by me-
mantine (P < 0:05). All treatments were the same as in (a). Compare bars 4 with 5 and 4/5 with 2/3. (c) Addition of OA (100 nM) to the hippocampal
slices extract resulted in 90% inhibition of PP-2A activity, and addition of memantine to this extract had no signiﬁcant eﬀect on the phosphatase
activity. d. Addition of memantine to the extract of cultured hippocampal slices in which PP-2A activity had been inhibited (40%) by OA for 24 h,
had no signiﬁcant eﬀect on the phosphatase activity (compare bars 3–5 with bars 1 and 2).
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the eﬀect of another two NMDA receptor antagonists on the
restoration of the OA-induced changes in PP-2A and in
CaMKII activities and phosphorylation of tau at Ser-262. For
these studies we selected DK and AP which antagonize
competitively the NMDA receptor through the strychnine-
insensitive glycine binding site and the glutamate binding site,
respectively [30]. We found that while 5 lM memantine re-
stored the OA-induced changes in the activities of PP-2A and
CaMKII and the phosphorylation of tau at Ser-262, neither
5–10 lM DK nor 5–10 lM AP could restore these changes
(Fig. 7). These studies suggested that in addition to its activity
as an NMDA receptor antagonist, memantine modulates PP-
2A signalling, and probably this latter eﬀect is involved in the
restoration of PP-2A activity and thereby the CaMKII activity
and the phosphorylation of tau to normal level.4. Discussion
Abnormal hyperphosphorylation of tau/neuroﬁbrillary de-
generation is pivotally involved in the pathogenesis of AD and
related tauopathies. One of the major goals of research on this
family of diseases is to develop drugs that can inhibit and re-
verse this lesion. We have discovered (i) that memantine can
inhibit and reverse the abnormal hyperphosphorylation and
aggregation of tau and NF-H/M and loss of MAP2 and the
associated neurodegeneration; and (ii) that these eﬀects of this
drug probably involve its previously unknown ability to
modulate PP-2A signaling, a property not detected in two
other NMDA receptor antagonists, i.e., DK and AP examined
in the present study.
Treatment of the OA-treated hippocampal slices in culture
with memantine practically completely restored the activities
Fig. 6. Eﬀect of glutamate on phosphorylation of tau at Ser-262 and on
PP and PKA activities in hippocampal slices in culture. Hippocampal
slices in culture were ﬁrst treated with 55 mM KCl, 10 min, to deblock
calcium channels and then with 0.3 mM glutamate 1 h, followed by
medium, 10 lM memantine or 15 lM MK801 for 3, 8, or 24 h. The
slices were then homogenized and either employed for [125I] Western
blots developed with PSer-262 tau antibody (a) or centrifuged at
16 000 g for 15 min, and the extracts used for assaying the activities
of PP-2A, CaMKII and MAPK (b,c, and d). The phosphatase and
kinase activities were expressed as percentage of the activity of control
samples incubated in medium alone. Bars represent meansS.D. ob-
tained from at least three independent assays. (b)–(d) 1, in medium,
3 h; 2, 0.3 mM glutamate, 1 h; 3, 0.3 mM glutamate, 1 h, followed by
medium 3 h; 4, 0.3 mM glutamate, 1 h, followed by 10 lMmemantine,
3 h; 5, 0.3 mM glutamate, 1 h, followed by 15 lM MK801, 3 h. (b)
After 1 h glutamate treatment, CaMKII activity increased to 180%
(P < 0:001) and the phosphorylation of tau at Ser-262 increased
markedly (a).
Fig. 7. Eﬀect of memantine, AP and DK on the OA-induced changes in
PP-2A and CaMKII activities and phosphorylation of tau at Ser-262.
Hippocampal slices in culture were treated with OA or medium alone
(cont) for 24 h, followed by a wash and then fresh medium without
(control) or with 5 or 10 lM (data not shown) of memantine (Mem),
AP or DK for another 24 h. Total phosphatase (a) (PP-2A/PP-1), PP-
2A (b) and CaMKII (c) activities as percentage of control and Western
blots (d) developed for the phosphorylation of tau at Ser-262 show that
only memantine but neither AP nor DK restore the OA-induced
changes to normal levels. Ns, 5 lg/lane, recombinant human brain
tau441; AD Ps, abnormally hyperphosphorylated tau isolated from an
AD brain. Rest of the details same as in Figs. 1–4.
L. Li et al. / FEBS Letters 566 (2004) 261–269 267of PP-2A, CaMKII and PKA, and phosphorylation of tau at
Ser-262 and Ser-214 but not of Ser-422 to normal state and
inhibited the associated neurodegeneration. Ser-262, Ser-214
and Ser-422, which are major abnormally phosphorylated tausites in AD, are phosphorylated by CaMKII, PKA and stress-
activated PKAs, respectively [9,27,28,31]. Ser-262 is the only
site abnormally hyperphosphorylated in the microtubule
binding domains and the phosphorylation of this site, which is
268 L. Li et al. / FEBS Letters 566 (2004) 261–269believed to be dynamically involved in tau’s activity in stabi-
lizing microtubules, results in inhibition of the microtubule
assembly-promoting activity of tau [17,32]. In the present
study, the reversal of the OA-induced cell death and the ab-
normal hyperphosphorylation of tau at Ser-262, but not at
Ser-422 to normal-like state by memantine is consistent with
the critical role of the former site in converting tau into an
inhibitor/toxic molecule. The phosphorylation of tau at Ser-
422 is apparently a later event because this site is phosphory-
lated in PHF and not cytosolic AD P-tau, and a recent study
has conﬁrmed its association to relatively mature tangles in
transgenic mice expressing tau P301L mutation [33]. The fact
that memantine treatment which completely reversed the PP-
2A-induced cell death had no eﬀect on phosphorylation of Ser-
422 suggests that this site might not be involved in cytotoxicity
but mainly in promoting tau’s self assembly into PHF/neuro-
ﬁbrillary tangles.
The immunocytochemical studies revealed abnormal hyper-
phosphorylation at Ser-262 and accumulation of tau in the OA-
treated cultures. The hyperphosphorylation of tau was found
primarily in the cells of the stratum oriens and the alveus and in
a focal area close to CA3. The cells of this area, some of which
might have migrated to this area in culture, showed especially
intense immunostaining. Abnormally hyperphosphorylated tau
was found to be aggregated in neurites resembling neuropil
threads seen in AD brain. Treatment of these cultures with
memantine restored in large part the hyperphosphorylation
and aggregation of tau to normal-like state during 24 h.
The OA-induced protein phosphorylation/dephosphoryla-
tion imbalance not only aﬀected tau but also revealed frag-
mented MAP2 staining in dendrites and hyperphosphorylation
and aggregation of NF-M/H subunits. Memantine reversed the
hyperphosphorylation of NF-H/M and increased the levels of
MAP2, consistent with the inhibition of neuroﬁbrillary de-
generation.
The reversal of the OA-induced protein phosphorylation/
dephosphorylation imbalance by memantine was most likely
through its eﬀect on PP-2A signaling pathway and neither
solely as an NMDA antagonist nor by any direct interaction
between OA and memantine. Memantine, which had no sig-
niﬁcant eﬀect on the activities of PP-2A, CaMKII and PKA on
normal control cultures, restored the activities of these en-
zymes and the abnormal hyperphosphorylation of tau both
when administered along with OA or after removal of OA
from the culture medium. In contrast, in vitro addition of
memantine to an extract of the cultured slices had no eﬀect on
the PP-2A activity inhibited with OA. Similarly, memantine
had no signiﬁcant eﬀect in vitro on the PP-2A activity of the
extract of hippocampal slices which were cultured in the
presence of OA. These in vitro ﬁndings showed the absence of
any direct interaction between memantine and PP-2A or OA.
We found that the treatment of the hippocampal slice cul-
tures with glutamate resulted in a marked increase in CaMKII
activity without any detectable eﬀect on the activities of PP-2A
and MAPK, suggesting that the stimulation of glutamate re-
ceptors, which include the NMDA receptors, produced an
intracellular Ca2þ inﬂux which stimulated CaMKII activity,
but had no eﬀect on either PP-2A activity or MAPK activity
which is regulated by PP-2A. Furthermore, unlike memantine,
DK and AP, two other NMDA receptor antagonists up to 10
lM concentrations studied, failed to restore the OA-induced
changes in PP-2A and CaMKII activities and the phosphory-lation of tau at Ser-262. Thus, the restoration of the activities
of PP-2A and the abnormal hyperphosphorylation of tau to
normal-like state by memantine probably involves the modu-
lation of PP-2A signaling, the exact nature of which remains to
be understood. Memantine has been reported to substitute for
the function of magnesium in blocking the overactivated
NMDA receptors in hippocampal slices [34,35]. Such an eﬀect
of memantine could also be involved in inhibiting the abnor-
mal hyperphosphorylation of tau through modulation of
CaMKII activity.
In conclusion, the OA-induced decrease in PP-2A activity
and increase in abnormal hyperphosphorylation of tau and
consequent neurodegeneration in adult rat hippocampal slices
in culture is a promising ex vivo model of tauopathies/neuro-
ﬁbrillary degeneration. Memantine modulates PP-2A signaling
and both inhibits and reverses neuroﬁbrillary degeneration in
this model. Memantine is known for its anti-excitotoxic and
enhanced neurotransmission activities and has been found to
inhibit the deterioration of the activities of daily living in
moderate to severe cases of AD [13,14]. This drug might also
be useful for AD and other tauopathies because of its ability to
inhibit neuroﬁbrillary degeneration through the restoration of
PP-2A, CaMKII and PKA activities and hyperphosphoryla-
tion of tau to normal levels.
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